• Arch Biopartners posted a net comprehensive loss of CAD 475,112 for the three months ended June 30, widening 96.11%.
• Loss per share widened to CAD 0.007 from CAD 0.004, while operating loss increased to CAD 472,172 from CAD 275,328.
• For the nine months ended June 30, net comprehensive loss widened to CAD 2.56 million from CAD 1.28 million, with no revenue.
• Operating loss widened to CAD 2.55 million from CAD 1.22 million, while cash fell to CAD 2,914 from CAD 167,460.
• Arch said LSALT peptide and cilastatin Phase II trials are ongoing, with its CKD platform in pre-clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.